| DC72941 |
LPC-233 |
LPC-233 (LPC233) is a highly potent and specific inhibitor of UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC (Ki=8.9 pM), specifically inhibits lipid A synthesis and displays outstanding antibiotic activities. |
|
| DC72942 |
MD-124 |
MD-124 is a potent antibiotic adjuvant against Gram-negative bacteria, sensitizes various Gram-negative bacterial species and strains, including multidrug resistant pathogens, toward existing antibiotics. |
|
| DC72943 |
MMV1091186 |
MMV1091186 (MMV 1091186) is an antimalarial compound that inhibit P. falciparum cytoplasmic isoleucyl tRNA synthetase (cIRS) with IC50 of 0.87 uM. |
|
| DC72944 |
MMV652103 |
MMV652103 is an antimalarial imidazopyridazine compound, exerts potent and selective cytotoxicity in ER+ breast cancer cells, potently inhibits the oncogenic PI4KB and PIK3C2G lipid kinases with IC50 of 1.7 and 0.085 uM, respectively. |
|
| DC72945 |
MSU-43085 |
MSU-43085 is a potent, orally bioavailable inhibitor of Mycobacterium tuberculosis (Mtb, EC50=120 nM) and M. abscessus survival, targets MmpL3. |
|
| DC72946 |
ND-011992 |
ND-011992 is a cytochrome bd oxidase (Cyt-bd) inhibitor, inhibits Mycobacterium tuberculosis respiratory complex I with IC50 of 0.12 uM, targets respiratory complex I and bo3 oxidase in addition to bd-I and bd-II oxidases. |
|
| DC72947 |
NSC116565 |
NSC116565 is a potent, time-dependent inhibitor of Mycobacterium tuberculosis (M.tb) ketol-acid reductoisomerase (KARI) with Ki of 95.4 nM. |
|
| DC72948 |
NTB-3119 |
NTB-3119 (NTB3119) is a novel benzothiopyranone derivative and anti-tuberculosis agent with potent in vitro activity against both drug-susceptible and drug-resistant tuberculosis clinical strains. |
|
| DC72949 |
OTB-658 |
OTB-658 (OTB658) is a novel oxazolidinone anti-tuberculosis agent, shows potent antibacterial activity against Mycobacterium tuberculosis, especially multi-drug resistant tuberculosis (MDR-TB) in vitro and in vivo. |
|
| DC72950 |
PKZ18-22 |
PKZ18-22 is a potency improved analog of PKZ18, inhibitiong tRNA-regulated gene expression of gram-positive bacteria, shows MIC value of 8 ug/mL against S. aureus. |
|
| DC72951 |
SAV13 |
SAV13 is a selective small molecule inhibitor of S. aureus exoprotein expression regulator (SaeR) withEC50 of 1.06 uM in luciferase assays, reduces expression of hla and other virulence factors. |
|
| DC72952 |
Savirin |
Savirin (S. aureus virulence inhibitor) is a small molecule inhibitor inhibiting agr quorum sensing in S. aureus by blocking the transcriptional function of AgrA. |
|
| DC72953 |
SF235 |
SF235 is a small-molecule inhibitor of macrophage infectivity potentiator (Mip) protein with IC50 and Ki 0.42 and 0.29 uM against B. pseudomallei Mip (BpMip) peptidyl-prolyl cis/trans isomerase (PPIase) activity, reduce B. pseudomallei virulence in vitro. |
|
| DC72954 |
SK-017154-O |
SK-017154-O is a specific and noncompetitive inhibitor of PelA, specifically inhibits PelA esterase activity with IC50 of 11 uM, inhibits Pel-dependent PA14 biofilms with IC50 of 1.8 uM. |
|
| DC72955 |
SMARt751 |
SMARt751 is a small molecule that interacts with the transcriptional regulator VirS of M. tuberculosis, up-regulates expression of the mymA operon, reverses resistance to ethionamide both in vitro and in vivo. |
|
| DC72956 |
SMT-738 |
SMT-738 is a small-molecule inhibitor of bacterial lipoprotein transport complex (LolCDE), shows potent and highly selective antimicrobial activity. |
|
| DC72957 |
TBAJ-5307 |
TBAJ-5307 is a broad spectrum anti-non-tuberculous mycobacteria (NTM) inhibitor targeting FO-domain of F1FO-ATP synthase, shows MIC50 of 4.5 nM and 6 nM against the Mab subsp. abscessus smooth strain and rough strain respectively. |
|
| DC72958 |
TBI-166 |
TBI-166 is a potential next-generation antituberculosis riminophenazine with activity against Mycobacterium tuberculosis (0.063 μg/ml). |
|
| DC72959 |
TPP8 |
TPP8 is a small molecule antibacterial inhibiting the ATPase of DNA gyrase with IC50 of 0.3 uM, binds and inhibits the ATPase domain of the gyrase B subunit, shows activity against M. abscessus strains with MIC of 0.04-0.2 uM. |
|
| DC72960 |
TXA707 |
TXA707 is the active metabolite of TXA709 and bacterial protein FtsZ inhibitor, maintains potent activity against S. aureus strains (e.g., MRSA, VRSA, DNSSA, and LNSSA) that are resistant to current SOC antibiotics. |
|
| DC72961 |
TXA709 |
TXA709 is a prodrug of FtsZ-targeting benzamide compound (TXA707) with enhanced metabolic stability, demonstrates improved pharmacokinetic properties, and superior in vivo antistaphylococcal efficacy (both oral and intravenous) relative to previously iden |
|
| DC72962 |
TXY436 |
TXY436 is an N-Mannich base derivative and FtsZ-directed prodrug of PC190723, TXY436 is effective against S. aureus can also target Gram-negative bacteria, such as Escherichia coli. |
|
| DC72963 |
TXY541 |
TXY541 is a 1-methylpiperidine-4-carboxamide prodrug of PC190723 and bacterial protein FtsZ inhibitor, TXY541 is efficacious in vivo in mouse models of systemic infection with both methicillin-sensitive and methicillin-resistant S. aureus. |
|
| DC72964 |
VU0026921 |
VU0026921 is a small molecule modulator of metal homeostasis in gram-positive pathogens, disrupts metal homeostasis in multiple Gram-positive bacteria, leading to increased reactive oxygen species and cell death. |
|
